Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M versus NEOPHAM 6 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M versus NEOPHAM 6 4.
AMINOSYN 3.5% M vs NEOPHAM 6.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a crystalline amino acid solution providing essential and nonessential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for anabolic processes and helps correct negative nitrogen balance.
NEOPHAM 6.4% is a sterile, nonpyrogenic, hypertonic solution of amino acids and glycerin used for parenteral nutrition. It provides essential and non-essential amino acids to support protein synthesis and energy metabolism, with glycerin serving as a non-glucose caloric source to reduce hyperglycemia. The amino acids are utilized for tissue repair and growth, while glycerin is metabolized via gluconeogenesis and glycolysis.
Intravenous infusion; typical adult dose: 1 to 1.5 g amino acids/kg/day (equivalent to 28.6 to 42.9 mL/kg/day of 3.5% solution). Administer via central or peripheral line at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion of 6.4% amino acid solution at 0.8-1.5 g/kg/day (equivalent to 12.5-23.4 mL/kg/day) for protein replenishment; typical adult dose 500-1000 mL/day infused at 1-2 mL/min.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is typically 0.5-2 hours in patients with normal renal and metabolic function, reflecting rapid uptake and metabolism by tissues. In hepatic or renal impairment, half-life may be prolonged due to decreased clearance.
Not applicable as a single entity; amino acids have varying half-lives (minutes to hours depending on individual amino acid and metabolic state). Clinical context: continuous infusion used for parenteral nutrition; no terminal elimination half-life defined for the mixture.
Amino acids in Aminosyn 3.5% M are primarily eliminated via metabolism (utilization for protein synthesis, energy, and other metabolic pathways). Minimal amounts are excreted unchanged in urine (less than 5% of infused amino acids) via glomerular filtration. There is no significant biliary or fecal elimination.
Renal elimination of absorbed amino acids and metabolites; minimal biliary/fecal excretion. >90% of infused amino acids are reincorporated into body protein or metabolized; excess nitrogen excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution